Search

Displaying results 4331 - 4340 of 10000 in total
  1. Drug

    Remacemide

    go.drugbank.com/drugs/DB06458
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Our team is working on the full update, which will be available soon. [L54673,L54668] … Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  3. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. … Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

    Synonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide
  4. Drug

    ENMD-1198

    go.drugbank.com/drugs/DB05959
    Experimental

  5. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

  6. Drug

    Typhoid Vi polysaccharide vaccine

    go.drugbank.com/drugs/DB10803
    ApprovedInvestigational

    It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. … The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

    Products: Typhim VI Solution for Injection in Multidose, Typhim Vi Injektionslösung in einer Fertigspritze
  7. Drug

    Platelet Lysate

    go.drugbank.com/drugs/DB15869
    Investigational

    Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.

  8. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE).

  9. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

  10. Drug

    Tolperisone

    go.drugbank.com/drugs/DB06264
    Investigational

    Based on existing clinical data, Tolperisone is not sedating and does not interact with alcohol. … It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves.